Pulmatrix Inc (PULM) Stock Price, Quote & News

Company Profile

Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical tri...

Industry: Biotechnology

Sector: Healthcare

Phone: 888 355 4440

Website: www.pulmatrix.com

Address:

945 Concord Street, Suite 1217, Framingham, United States

Nakom Jun. 25 at 3:20 PM

$PULM Don’t get sucked into chasing it. Just accumulate slowly. I picked up 48 shares this morning. Plan for another 150 shares over the next 2 days. Doesn’t sound like much but as I said all along the small purchases add up.

0 · Reply

Nakom Jun. 25 at 10:20 AM

$PULM Reverse merger coming soon.

0 · Reply

Nakom Jun. 24 at 2:41 PM

$PULM Look at the stacking that is being done on the bids and ask. Also look at the gap. Lots of dark pool buying and selling going on also. This bitch is wond so tight that when it finally takes flight we will be traveling at the speed of sound. Insane I tell you. With that said it’s a great time to buy.

0 · Reply

Busstamove Jun. 23 at 5:45 PM

$PULM ready to squeeze again

1 · Reply

Nakom Jun. 23 at 4:11 PM

$PULM I think everyone is hugely underestimating the value of the assets. Just to get a IND approved is a big deal. Taking it through a phase 1 trial and having the FDA approval for a phase 2 trial is yet another milestone. Then completing a phase 2 trial and move into a phase 3 trial is quite the accomplishment. Actually a phase 2 trial and phase 3 trial are actually quite similar. In a phase 2 trial you’ve proven the drug works like it is suppose to. Phase 3 trial is a lot more patience involved. With that said Pulmatrix drugs have checked many of the boxes. Now take in everything I have pointed out the assets are worth atleast 40 million. Good luck with your investment.

1 · Reply

AveraveJoeTrader Jun. 23 at 1:50 PM

$PULM An absolute steal here..

0 · Reply

Nakom Jun. 23 at 1:41 PM

$PULM Picked up another 50 shares. Will be back for more tomorrow. Slow and steady wins the race.

0 · Reply

Nakom Jun. 23 at 1:36 AM

$PULM We’re getting close. I can feel it coming in the air tonight. Well a you told me we were going bankrupt I would not believe a word you said oh lord. What a classic and so appropriate for what’s about to come. Super bullish!!!

0 · Reply

Vinniesb Jun. 22 at 5:10 PM

$PULM

0 · Reply

AveraveJoeTrader Jun. 22 at 4:58 PM

Back in $PULM $1.61 pressure building here..

0 · Reply

Pulmatrix Registration statement: Registration filing

2026-06-04T10:16:34.000Z - 21 days ago

Pulmatrix files to sell 490,910 shares of common stock for holders

May 15, 2026, 8:20 AM EDT - 5 weeks ago

Pulmatrix Announces First Quarter 2026 Financial Results

May 15, 2026, 7:00 AM EDT - 5 weeks ago

Pulmatrix Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 5 weeks ago

Pulmatrix Earnings release: Q1 2026

Apr 21, 2026, 8:00 AM EDT - 2 months ago

Pulmatrix Announces Closing of Preferred Stock Transaction as Part of Planned Merger

2026-03-26T12:10:12.000Z - 3 months ago

Pulmatrix to merge with Eos Senolytix

Mar 26, 2026, 8:00 AM EDT - 3 months ago

Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan

2026-03-02T13:06:59.000Z - 4 months ago

Pulmatrix announces Cullgen terminates merger agreement

Mar 2, 2026, 8:00 AM EST - 4 months ago

Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities

Feb 26, 2026, 8:05 AM EST - 4 months ago

Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results

Feb 26, 2026, 8:00 AM EST - 4 months ago

Pulmatrix Annual report: Q4 2025

Feb 26, 2026, 8:00 AM EST - 4 months ago

Pulmatrix Earnings release: Q4 2025

2025-12-18T13:17:12.000Z - 6 months ago

Pulmatrix and Cullgen continue to pursue merger

Dec 18, 2025, 8:05 AM EST - 6 months ago

Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives

2025-10-16T12:21:23.000Z - 9 months ago

Pulmatrix reports Q3 EPS (24c) vs. (71c) last year

2025-10-16T12:10:51.000Z - 9 months ago

Pulmatrix to potentially divest its patent portfolio for iSPERSE technology

Oct 16, 2025, 8:05 AM EDT - 9 months ago

Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets

Oct 16, 2025, 7:00 AM EDT - 9 months ago

Pulmatrix Quarterly report: Q3 2025

Oct 16, 2025, 7:00 AM EDT - 9 months ago

Pulmatrix Earnings release: Q3 2025

2025-08-06T12:16:43.000Z - 11 months ago

Pulmatrix to potentially divest its patent portfolio for iSPERSE technology

Aug 6, 2025, 8:05 AM EDT - 11 months ago

Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets

Aug 5, 2025, 6:00 PM EDT - 11 months ago

Pulmatrix Quarterly report: Q2 2025

Aug 5, 2025, 6:00 PM EDT - 11 months ago

Pulmatrix Earnings release: Q2 2025

2025-06-25T15:20:32.000Z - 1 year ago

Pulmatrix trading resumes

2025-06-25T15:15:23.000Z - 1 year ago

Pulmatrix trading halted, volatility trading pause

2025-06-23T17:34:11.000Z - 1 year ago

Pulmatrix trading halted, volatility trading pause

2025-06-23T17:33:41.000Z - 1 year ago

Pulmatrix trading resumes

May 15, 2025, 8:05 AM EDT - 1 year ago

Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets

May 14, 2025, 6:00 PM EDT - 1 year ago

Pulmatrix Earnings release: Q1 2025

May 14, 2025, 6:00 PM EDT - 1 year ago

Pulmatrix Quarterly report: Q1 2025

May 9, 2025, 4:00 PM EDT - 1 year ago

PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM

Mar 21, 2025, 8:05 AM EDT - 1 year ago

Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets

Mar 21, 2025, 8:00 AM EDT - 1 year ago

Pulmatrix Annual report: Q4 2024

Mar 21, 2025, 8:00 AM EDT - 1 year ago

Pulmatrix Earnings release: Q4 2024

Nov 15, 2024, 8:00 AM EST - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders

GRDX

2024-11-13T14:50:17.000Z - 1 year ago

Pulmatrix trading resumes

2024-11-13T14:07:00.000Z - 1 year ago

Pulmatrix announces merger agreement with Cullgen

Nov 13, 2024, 9:00 AM EST - 1 year ago

Pulmatrix and Cullgen Announce Proposed Merger

2024-11-13T13:55:15.000Z - 1 year ago

Pulmatrix trading halted, news pending

Nov 13, 2024, 6:00 AM EST - 1 year ago

Pulmatrix Transcript: M&A Announcement

Nov 13, 2024, 6:00 AM EST - 1 year ago

Pulmatrix Slides: M&A Announcement

2024-11-08T15:35:37.000Z - 1 year ago

Pulmatrix reports Q3 EPS (71c) vs. ($1.03) last year

2024-11-08T15:35:10.000Z - 1 year ago

Pulmatrix sees cash runway into 4Q26

Nov 8, 2024, 10:26 AM EST - 1 year ago

Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 8, 2024, 7:00 AM EST - 1 year ago

Pulmatrix Quarterly report: Q3 2024

Nov 8, 2024, 7:00 AM EST - 1 year ago

Pulmatrix Earnings release: Q3 2024

Nov 8, 2024, 7:00 AM EST - 1 year ago

Pulmatrix Proxy statement: Proxy Filing

Aug 13, 2024, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 13, 2024, 7:00 AM EDT - 2 years ago

Pulmatrix Quarterly report: Q2 2024

Aug 13, 2024, 7:00 AM EDT - 2 years ago

Pulmatrix Earnings release: Q2 2024

May 29, 2024, 8:45 AM EDT - 2 years ago

Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation

MNKD

May 17, 2024, 8:00 AM EDT - 2 years ago

Pulmatrix Registration statement: Registration Filing

May 15, 2024, 9:35 AM EDT - 2 years ago

Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)

May 10, 2024, 8:05 AM EDT - 2 years ago

Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 10, 2024, 7:00 AM EDT - 2 years ago

Pulmatrix Quarterly report: Q1 2024

May 10, 2024, 7:00 AM EDT - 2 years ago

Pulmatrix Earnings release: Q1 2024

Mar 28, 2024, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Pulmatrix Annual report: Q4 2023

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Pulmatrix Earnings release: Q4 2023

Jan 8, 2024, 9:00 AM EST - 2 years ago

Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives

Nov 9, 2023, 9:05 AM EST - 2 years ago

Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 8, 2023, 6:00 PM EST - 2 years ago

Pulmatrix Quarterly report: Q3 2023

Nov 8, 2023, 6:00 PM EST - 2 years ago

Pulmatrix Earnings release: Q3 2023

Sep 19, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine

Aug 23, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole

Aug 10, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 10, 2023, 7:00 AM EDT - 3 years ago

Pulmatrix Quarterly report: Q2 2023

Aug 10, 2023, 7:00 AM EDT - 3 years ago

Pulmatrix Earnings release: Q2 2023

Jul 11, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

Jun 15, 2023, 9:20 AM EDT - 3 years ago

Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society

Jun 15, 2023, 2:00 AM EDT - 3 years ago

Pulmatrix Press release: Study Update

Jun 5, 2023, 6:45 AM EDT - 3 years ago

Pulmatrix Slides: Corporate Presentation

Jun 2, 2023, 8:00 AM EDT - 3 years ago

Pulmatrix Proxy statement: Proxy Filing

May 24, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention

May 12, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update

May 12, 2023, 7:00 AM EDT - 3 years ago

Pulmatrix Quarterly report: Q1 2023

May 12, 2023, 7:00 AM EDT - 3 years ago

Pulmatrix Earnings release: Q1 2023

May 2, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Supports World Asthma Day 2023

Mar 30, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update

Mar 30, 2023, 7:00 AM EDT - 3 years ago

Pulmatrix Annual report: Q4 2022

Mar 30, 2023, 7:00 AM EDT - 3 years ago

Pulmatrix Earnings release: Q4 2022

Feb 6, 2023, 9:10 AM EST - 3 years ago

Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma

Feb 3, 2023, 7:00 AM EST - 3 years ago

Pulmatrix Slides: KOL Event

Jan 25, 2023, 9:05 AM EST - 3 years ago

Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment"

Jan 23, 2023, 9:05 AM EST - 3 years ago

Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology

Jan 4, 2023, 9:05 AM EST - 3 years ago

Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine

Nov 14, 2022, 7:00 AM EST - 3 years ago

Pulmatrix Quarterly report: Q3 2022

Nov 14, 2022, 7:00 AM EST - 3 years ago

Pulmatrix Earnings release: Q3 2022

Nov 10, 2022, 9:05 AM EST - 3 years ago

Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Sep 26, 2022, 9:00 AM EDT - 4 years ago

Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine

Aug 10, 2022, 7:00 AM EDT - 4 years ago

Pulmatrix Quarterly report: Q2 2022

Aug 10, 2022, 7:00 AM EDT - 4 years ago

Pulmatrix Earnings release: Q2 2022

Aug 8, 2022, 9:05 AM EDT - 4 years ago

Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Jul 12, 2022, 9:00 AM EDT - 4 years ago

Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine

Jun 11, 2022, 7:00 AM EDT - 4 years ago

Pulmatrix Quarterly report: Q1 2022

Jun 11, 2022, 7:00 AM EDT - 4 years ago

Pulmatrix Earnings release: Q1 2022

May 12, 2022, 9:05 AM EDT - 4 years ago

Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update

May 2, 2022, 8:00 AM EDT - 4 years ago

Pulmatrix Proxy statement: Proxy Filing

Apr 29, 2022, 8:00 AM EDT - 4 years ago

Pulmatrix Proxy statement: Proxy Filing

Mar 29, 2022, 9:05 AM EDT - 4 years ago

Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update

Mar 21, 2022, 8:05 AM EDT - 4 years ago

Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD

Mar 17, 2022, 4:05 PM EDT - 4 years ago

Pulmatrix Regains Compliance With Nasdaq Listing Requirements

Mar 1, 2022, 9:00 AM EST - 4 years ago

Pulmatrix Announces Expansion of Executive Leadership Team to Progress Clinical Pipeline

Feb 24, 2022, 4:05 PM EST - 4 years ago

Pulmatrix, Inc. Announces 1-for-20 Reverse Stock Split

Feb 1, 2022, 9:00 AM EST - 4 years ago

Pulmatrix Issues Letter to Stockholders

Feb 1, 2022, 7:00 AM EST - 4 years ago

Pulmatrix Proxy statement: Proxy Filing

Dec 30, 2021, 7:00 AM EST - 4 years ago

Pulmatrix Proxy statement: Proxy Filing

Dec 30, 2021, 7:00 AM EST - 4 years ago

Pulmatrix Proxy statement: Proxy Filing

Dec 20, 2021, 7:00 AM EST - 4 years ago

Pulmatrix Proxy statement: Proxy Filing

Dec 17, 2021, 4:30 PM EST - 4 years ago

Pulmatrix Announces Closing of $6.75 Million Registered Direct Offering

Nakom Jun. 25 at 3:20 PM

0 · Reply

Nakom Jun. 25 at 10:20 AM

$PULM Reverse merger coming soon.

0 · Reply

Nakom Jun. 24 at 2:41 PM

0 · Reply

Busstamove Jun. 23 at 5:45 PM

$PULM ready to squeeze again

1 · Reply

Nakom Jun. 23 at 4:11 PM

1 · Reply

AveraveJoeTrader Jun. 23 at 1:50 PM

$PULM An absolute steal here..

0 · Reply

Nakom Jun. 23 at 1:41 PM

$PULM Picked up another 50 shares. Will be back for more tomorrow. Slow and steady wins the race.

0 · Reply

Nakom Jun. 23 at 1:36 AM

0 · Reply

Vinniesb Jun. 22 at 5:10 PM

$PULM

0 · Reply

AveraveJoeTrader Jun. 22 at 4:58 PM

Back in $PULM $1.61 pressure building here..

0 · Reply

Gugger Jun. 22 at 2:26 PM

$PULM added 10K more 😜

1 · Reply

hippo_hungry Jun. 22 at 1:11 PM

$PULM if that wasn’t insider trading I don’t know what was..

0 · Reply

BigBoyTroy Jun. 22 at 7:59 AM

$LPA $AMBO $HYPD Free discord link in my stoctwits Profile .Boom Town Trades $PULM

1 · Reply

BigBoyTroy Jun. 22 at 7:54 AM

$LPA $HYPD $AMBO $PULM Free discord link in my stoctwits Profile Boom Town Trades Discord

0 · Reply

Nakom Jun. 21 at 6:41 PM

$PULM So they said when the reverse merger was announced they were targeting mid summer. Today is the 1st day of summer. Let the count down start!!! Beyond super bullish. HAPPY FATHERS DAY!!!

0 · Reply

Nakom Jun. 20 at 6:09 PM

$PULM Eos SENOLYTIX has more going for it then people think. After researching them I now understand why Pulmatrix is doing a reverse merger with them. I can tell you from my research that there is 0 dollars baked into Pulmatrix stock for the sale of the assets currently.

1 · Reply

JLCw Jun. 19 at 9:36 PM

FINAL WATCHLIST $GPUS AI + crypto + robotics, needs 0.95 break $NXGL slow grind turnaround, needs confirmation $PULM merger story, timing-dependent $ACON fundamentals are strong, but need volume Have a great long weekend and happy Father's Day! - JL

1 · Reply

AveraveJoeTrader Jun. 18 at 10:15 PM

$PULM Back in $1.54 for a move back over $1.6

2 · Reply

Nakom Jun. 18 at 9:09 PM

$PULM can’t remember the last time there was after hour trading or during trading hours that we saw this much trading being done. All is good. 👍. Have a great weekend fellow longs!!!

1 · Reply

hippo_hungry Jun. 18 at 9:00 PM

$PULM welcome new bag holders !!

0 · Reply

AveraveJoeTrader Jun. 18 at 8:52 PM

$PULM Interesting AH volume..added $1.61

0 · Reply

topstockalerts Jun. 18 at 8:44 PM

$PULM this just flipped real quick… nice move starting

0 · Reply

Market Cap	5.48M
Revenue (ttm)	0.00
Net Income (ttm)	-5.16M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	137,927
Avg Vol	58,834
Day's Range	N/A - N/A
Shares Out	3.65M
Stochastic %K	64%
Beta	1.95
Analysts	Strong Buy
Price Target	$10.00